Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and benefits of intra-articular regenerative injections for hemophilic arthropathy
RBR-22xgxrwPhase 2Recruiting
- Sponsor
- Federal University of Rio de Janeiro
- Start
- Mar 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of platelet-rich plasma and hyaluronic acid in hemophilic arthropathy (HA), sponsored by Federal University of Rio de Janeiro. Primary endpoints: Safety and Clinical benefit. Started Mar 2026; status: recruiting.
02
Drugs
platelet-rich plasmahyaluronic acid
03
Conditions
hemophilic arthropathy (HA)
Beyond the preview
Go deeper on RBR-22xgxrw.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-22xgxrw.